Viking Therapeutics, Inc. – LSE:0VQA.L
Viking Therapeutics stock price today
Viking Therapeutics stock price monthly change
Viking Therapeutics stock price quarterly change
Viking Therapeutics stock price yearly change
Viking Therapeutics key metrics
Market Cap | 4.37B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.92 |
Revenue | N/A |
EBITDA | -114.21M |
Income | -93.72M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeViking Therapeutics stock price history
Viking Therapeutics stock forecast
Viking Therapeutics financial statements
| Jun 2023 | 0 | -19.22M | |
|---|---|---|---|
| Sep 2023 | 0 | -22.53M | |
| Dec 2023 | 436K | -24.60M | -5643.35% |
| Mar 2024 | 0 | -27.35M |
| Sep 2025 | 0 | -28.90M | |
|---|---|---|---|
| Oct 2025 | 0 | -35.85M | |
| Dec 2025 | 0 | -37.97M | |
| Mar 2026 | 0 | -29.16M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 400693000 | 14.57M | 3.64% |
|---|---|---|---|
| Sep 2023 | 382663000 | 14.42M | 3.77% |
| Dec 2023 | 368490000 | 20.07M | 5.45% |
| Mar 2024 | 967518000 | 33.62M | 3.48% |
| Jun 2023 | -11.43M | -204.48M | 267.07M |
|---|---|---|---|
| Sep 2023 | -19.65M | -12.53M | -74K |
| Dec 2023 | -17.64M | 35.73M | 188K |
| Mar 2024 | -6.13M | -459.79M | 606.03M |
Viking Therapeutics alternative data
| Aug 2023 | 21 |
|---|---|
| Sep 2023 | 22 |
| Oct 2023 | 22 |
| Nov 2023 | 23 |
| Dec 2023 | 23 |
| Jan 2024 | 23 |
| Feb 2024 | 23 |
| Mar 2024 | 27 |
| Apr 2024 | 27 |
| May 2024 | 28 |
| Jun 2024 | 28 |
| Jul 2024 | 28 |
Viking Therapeutics other data
| Patent |
|---|
Application Filling date: 6 May 2022 Issue date: 18 Aug 2022 |
Grant Utility: Use of thyroid beta-agonists Filling date: 24 Apr 2017 Issue date: 7 Jun 2022 |
Application Filling date: 4 Dec 2019 Issue date: 20 Jan 2022 |
Grant Filling date: 17 Nov 2017 Issue date: 21 Dec 2021 |
Application Filling date: 18 Mar 2019 Issue date: 28 Jan 2021 |
Application Filling date: 8 Jul 2020 Issue date: 29 Oct 2020 |
Application Filling date: 4 Jun 2018 Issue date: 11 Jun 2020 |
Application Filling date: 17 Nov 2017 Issue date: 14 Nov 2019 |
Application Filling date: 24 Apr 2017 Issue date: 24 Oct 2019 |
Application Filling date: 13 Sep 2017 Issue date: 22 Aug 2019 |
| Insider | Compensation |
|---|---|
| Dr. Brian Lian Ph.D. (1966) Pres, Chief Executive Officer & Director | $735,000 |
Mr. Gregory S. Zante Senior Vice President of Fin. | |
| Mr. Michael Morneau Vice President of Fin. & Admin. | |
Ms. Marianne Mancini Senior Vice President of Clinical Operations |
-
What's the price of Viking Therapeutics stock today?
One share of Viking Therapeutics stock can currently be purchased for approximately $4.6.
-
When is Viking Therapeutics's next earnings date?
Unfortunately, Viking Therapeutics's (0VQA.L) next earnings date is currently unknown.
-
Does Viking Therapeutics pay dividends?
No, Viking Therapeutics does not pay dividends.
-
How much money does Viking Therapeutics make?
Viking Therapeutics has a market capitalization of 4.37B.
-
What is Viking Therapeutics's stock symbol?
Viking Therapeutics, Inc. is traded on the LSE under the ticker symbol "0VQA.L".
-
What is Viking Therapeutics's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Viking Therapeutics?
Shares of Viking Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Viking Therapeutics's key executives?
Viking Therapeutics's management team includes the following people:
- Dr. Brian Lian Ph.D. Pres, Chief Executive Officer & Director(age: 59, pay: $735,000)
- Mr. Gregory S. Zante Senior Vice President of Fin.
- Mr. Michael Morneau Vice President of Fin. & Admin.
- Ms. Marianne Mancini Senior Vice President of Clinical Operations
-
How many employees does Viking Therapeutics have?
As Jul 2024, Viking Therapeutics employs 28 workers, which is 4% more then previous quarter.
-
When Viking Therapeutics went public?
Viking Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 8 Oct 2018.
-
What is Viking Therapeutics's official website?
The official website for Viking Therapeutics is vikingtherapeutics.com.
-
Where are Viking Therapeutics's headquarters?
Viking Therapeutics is headquartered at 9920 Pacific Heights Boulevard, San Diego, CA.
-
How can i contact Viking Therapeutics?
Viking Therapeutics's mailing address is 9920 Pacific Heights Boulevard, San Diego, CA and company can be reached via phone at 858 704 4660.
Viking Therapeutics company profile:
Viking Therapeutics, Inc.
vikingtherapeutics.comLSE
30
Medical - Pharmaceuticals
Healthcare
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
San Diego, CA 92121
:
ISIN: US92686J1060
:
